Redwood City, United States
Pulmonx Corporation is a Health Care startup that aims to improve the breathing and quality of life for emphysema and advanced COPD patients. Founded in 1998 and headquartered in the United States, the company has developed the Zephyr Endobronchial Valve, a minimally invasive treatment for COPD/emphysema. The one-time procedure, which received a $66.00M Series H investment on 05 May 2020 from HealthQuest Capital, Adage Capital Management, Ally Bridge Group, PFM Health Sciences, and Rock Springs Capital, is performed by bronchoscopy and requires no cutting or incisions.
The Zephyr Endobronchial Valve treatment involves placing on average 4 tiny valves in the airways to block off the diseased parts of the lung, allowing trapped air to escape until the lobe is reduced. This reduction of hyperinflation enables the healthier parts of the lungs to expand and take in more air, resulting in patients being able to breathe easier and have less shortness of breath. However, it's important to note that complications of the treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea, and, in rare cases, death.
The Pulmonx Zephyr Endobronchial Valves are implantable bronchial valves indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valve is contraindicated for certain patient groups and should be used with caution in treating others. It is imperative that the Zephyr Endobronchial Valve System Instructions are referenced for complete information on indications, contraindications, and precautions.
